REALVNC
9.6.2022 15:02:03 CEST | Business Wire | Press release
VNC Connect by RealVNC, the remote access service used by hundreds of millions of people worldwide, was audited by Cure53 , the Berlin, Germany-based IT security consultancy who have also audited other industry leading software such as Mozilla VPN, 1Password and Bitwarden. The comprehensive audit, which took 86 person days and included VNC Server and VNC Viewer on Linux, Windows and Mac, VNC Viewer for iOS and Android, the VNC Connect management portal and backend services, found 38 security-relevant discoveries, none of which were critical and only three were deemed high severity, and these were fixed immediately. The report states, in conclusion, that RealVNC places a strong focus on the security posture of all its components.
“As the technologists responsible for bringing remote access to the mass market, we are today setting new standards and expectations for security in the face of the challenges of the modern IT environment. IT buyers of remote access technologies should expect no less than independent and comprehensive third-party validation of vendor claims. This is especially true for remote access software where the stakes are high, and a mistake could be reputationally damaging or even existential. With Cure53’s report, buyers can be confident that choosing RealVNC as their remote access vendor will never be a regret,” said Adam Greenwood-Byrne, CEO of RealVNC.
A white box security audit is significantly more in-depth than the more common black box penetration test (which RealVNC also commissions by an external organization annually), as the auditors have access to all of the source code, binaries and API/protocol documentation. Of the 38 vulnerabilities found across the range of software and services tested, 32 have been properly addressed — with the fixes confirmed by Cure53 — while the other six were flagged as either false-alerts or works-as-intended and evaluated to be of lower risk.
“At RealVNC, we operate from the standpoint that no company should ever take a vendor’s word for it when they claim their software is secure, which is why we chose to complete a white box audit with a highly regarded security consultancy to prove it,” said Andrew Woodhouse, CIO of RealVNC.
The Cure53 team is highly motivated to find issues when completing white box penetration tests. The fact that no critical threats were found reinforces RealVNC’s focus on ensuring its customers remain safe from threats when using VNC Connect.
“Cure53 is happy to state that test preparation, test execution and also the fix verification, which is one of the most important parts of such an audit, went smoothly and professionally. It is clear that RealVNC has demonstrated a genuine interest in ensuring VNC Connect's security and is prepared and committed to maintaining the high standards we have observed,” said Dr.-Ing. Mario Heiderich, Founder of Cure53.
Headquartered in Cambridge, RealVNC's products for desktop, mobile and embedded platforms make it easy for users to access and operate devices remotely while enabling remote users to work with technicians to resolve problems easily.
“We’re not shying away from any of the issues the report found. We actively fixed issues as they came up and, as security is an ever changing landscape, we’ll continue to ensure the security of VNC Connect in future iterations of the service,” said Ben May, Head of Cyber Security at RealVNC.
To review Cure53's summary of the audit, click here , and to learn more about why RealVNC chose to conduct a Cure53 audit, click here .
ABOUT REALVNC
RealVNC’s secure remote access and management software is used by hundreds of millions of people worldwide. Their software helps organizations cut costs and improve the quality of supporting remote devices and applications, as well as enabling remote working. RealVNC is the original, UK-based, inventor of VNC remote access software and they support an unrivaled mix of desktop, mobile and embedded platforms.
ABOUT CURE53
Cure53 offers classic black-box penetration tests (zero-knowledge) as well as white-box tests and code audits. Web application and mobile app developers speak many languages and so do we. From classic languages such as PHP, JavaScript, ActionScript, Java, Ruby, Python and Perl to more exotic candidates like web back-ends written in C++ and Delphi – we've seen them.
Since Cure53 was founded in 2007, we have performed hundreds of penetration tests against all kinds of web applications, online services, hardware interfaces, mobile applications, libraries and crypto tools. We value manual and thorough tests, human interaction and communication and a short yet-to-the-point penetration test report without overhead or pie charts no one wants to see.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005211/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
